FDA Grants Orphan Drug and Rare Pediatric Disease Designations to UTR Therapeutics' MYCN-Targeting RNA Therapeutic
核心洞察
The FDA granted Orphan Drug Designation to UTRxMYCN M1-14 (搜索) for soft tissue sarcoma (搜索), including rhabdomyosarcoma (搜索), and Rare Pediatric Disease Designation for rhabdomyosarcoma.
UTRxMYCN M1-14 (搜索) uses ultra-targeted 3'UTR engineering to degrade oncogenic MYCN (搜索) mRNA via the nonsense-mediated decay pathway while sparing healthy mRNA.
MYCN (搜索) is an intrinsically disordered transcription factor with no binding pocket, and no clinically approved therapies directly target it.
UTR Therapeutics Inc. (搜索) announced on Sept. 29, 2026 that the U.S. Food and Drug Administration has granted Orphan Drug Designation to 3'UTRMYCN M1-14 (UTRxMYCN M1-14 (搜索)) for the treatment of soft tissue sarcoma (搜索), including rhabdomyosarcoma (搜索) (RMS), and Rare Pediatric Disease Designation for the treatment of rhabdomyosarcoma. The New York-based company said the designations reflect the candidate's targeting of MYCN (搜索) (N-MYC) in rare, aggressive soft tissue sarcomas.
An RNA platform aimed at an undruggable target
The company's core technology, ultra-targeted 3'UTR engineering, was invented by Chidiebere U. Awah, M.D., Ph.D., chief executive officer of UTR Therapeutics. According to the company, the approach targets the oncogenic mRNA of undruggable genes, overwrites their endogenous oncogenic mRNA messages, and triggers them for degradation by the nonsense-mediated decay pathway, eliminating the diseased mRNA while sparing the healthy mRNA.
MYCN (搜索) is a basic helix-loop-helix transcription factor belonging to the MYC superfamily. It is an intrinsically disordered transcription factor with no binding pocket, a structural feature the company says has rendered it undruggable and beyond the reach of conventional methods. MYCN is a defining oncogenic driver of aggressive soft tissue sarcomas, including fusion-positive rhabdomyosarcoma (搜索), described as the most common soft tissue sarcoma (搜索) in children. The company states that MYCN contributes to a subset of the more than 80 soft tissue sarcoma subtypes affecting children and adults, and that there are currently no clinically approved therapies that directly target MYCN.
Preclinical activity in MYCN-driven rhabdomyosarcoma
In preclinical studies, UTRxMYCN M1-14 (搜索) reliably targeted and degraded oncogenic MYCN (搜索) in aggressive MYCN-driven rhabdomyosarcoma (搜索), including fusion-positive disease. The drug achieved on-target specificity and therapeutic efficacy, with dose-dependent inhibition of MYCN, tumor inhibition, and inhibition of liver and lung metastasis while remaining safe, according to the company.
"The ODD and RPDD designations granted to UTRxMYCN M1-14 (搜索) by the U.S. FDA validate the UTR Therapeutics platform technology and the potential of UTRxMYCN M1-14 to address several aggressive sarcomas that represent serious unmet needs in the U.S. and worldwide," said David T. Asuzu, M.D., chief medical officer of UTR Therapeutics.
What the designations provide
The FDA grants Orphan Drug Designation to drugs and biologics intended to treat diseases affecting fewer than 200,000 people in the United States. ODD provides seven years of U.S. market exclusivity upon approval, a tax credit for qualified clinical testing costs, and an exemption from prescription drug user fees.
Rare Pediatric Disease Designation is granted to drugs for serious or life-threatening diseases that primarily affect individuals under 18. RPDD is a prerequisite for a Rare Pediatric Disease Priority Review Voucher, which may be awarded upon FDA approval of the asset, subject to the FDA's eligibility criteria at the time of approval. The company noted that the Priority Review Voucher has been recorded to trade at values beyond $195 million.
Pipeline and delivery
UTR Therapeutics describes itself as advancing a first-in-class RNA Overwriting platform delivered by a proprietary Iron Oxide Nanocage (ION) delivery system. The platform is designed to identify and kill cancer-driving transcription factors that have resisted conventional drug modalities. The company reports clinical-ready assets spanning c-MYC (搜索), MYCN (搜索), TEAD1 (搜索), YAP1 (搜索), and HER2 (搜索) (ERBB2), as well as assets for neurodegenerative disorders.